scholarly journals Attempts to infect pigs with Coxsackie virus type B5

1974 ◽  
Vol 73 (1) ◽  
pp. 85-96 ◽  
Author(s):  
A. J. M. Garland ◽  
J. A. Mann
Keyword(s):  
Virus Type ◽  
Neutralizing Antibody ◽  
Coxsackie Virus ◽  
Virus Population ◽  
Serological Relationship ◽  
Anamnestic Response ◽  
Transient Rise ◽  
Buccal Swabs ◽  
Antibody Titres ◽  
Vesicular Disease

SUMMARYDespite the existence of a close serological relationship between the entero-viruses Swine Vesicular Disease (SVD) and Coxsackie type B5 (Cx B5), the administration of this Coxsackie virus type to susceptible pigs by various routes failed to produce clinical disease.Viraemia was not detected after exposure but virus was recovered intermittently from faeces and buccal swabs. A mixed virus population was demonstrated in faecal cultures from some pigs, including Coxsackie virus type B5 and other agents, presumably native pig enteroviruses. The Coxsackie virus persisted in faeces in declining amounts for up to 8 days after primary exposure.Serum neutralizing antibody showed a transient rise to Coxsackie virus, reaching a peak at 14 days and declining below demonstrable titres by 28 days after exposure. The antibody titres attained were proportional to the dose of virus administered and the degree of neutralization was very similar to both SVD and Cx B5 viruses.On cross challenge by exposure to SVD virus 28 days after exposure to Cx B5 virus, most animals (5/6) succumbed with typical vesicular lesions, although the serum neutralizing antibody titres showed a characteristically anamnestic response to both viruses.

scholarly journals Antibody responses in buffalos immunized with Clostridium perfringens beta and epsilon toxoids

2001 ◽  
Vol 46 (No. 9–10) ◽  
pp. 241-243 ◽  
Author(s):  
S. Rahman M ◽  
K. Baek B ◽  
T. Hong S ◽  
H. Lee J
Keyword(s):  
Antibody Titre ◽  
Clostridium Perfringens ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Control Group ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Antibody Titres ◽  
Group A ◽  
And Control

The antibody responses to toxoids were measured to investigate whether Clostridium perfringens beta and epsilon toxoids induced protective humoral immune responses in buffalos. Total of 24 buffalos were divided into 4 groups (n = 6), beta toxoid, epsilon toxoid, combination and control groups. These buffalo groups were administered each of the designated toxoids. Immunizations in the beta and epsilon toxoid groups induced strong antibody responses. The neutralizing antibody titres from the beta and epsilon toxoid groups were equally log101.2 on day 21 after inoculation whereas there was no antibody titre detected from the control group. A statistically significant (P < 0.01) increase in antibody titre was observed from day 0 to day 14 and 21 after inoculation. The antibody production did not vary significantly due to day of inoculation and toxoid interactions.

scholarly journals Highly Selective Transmission Success of Dengue Virus Type 1 Lineages in a Dynamic Virus Population: An Evolutionary and Fitness Perspective

iScience ◽  
2018 ◽  
Vol 6 ◽  
pp. 38-51 ◽  
Author(s):  
Carmen Koo ◽  
Wei Ping Tien ◽  
Helen Xu ◽  
Janet Ong ◽  
Jayanthi Rajarethinam ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Virus Type ◽  
Virus Population ◽  
Transmission Success

scholarly journals Development of a homology model for clade A human immunodeficiency virus type 1 gp120 to localize temporal substitutions arising in recently infected women

2004 ◽  
Vol 85 (6) ◽  
pp. 1479-1484
Author(s):  
Mary Poss ◽  
David C. Holley ◽  
Roman Biek ◽  
Harold Cox ◽  
John Gerdes
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Envelope Gene ◽  
Virus Population ◽  
Gene Sequences ◽  
Virus Diversity ◽  
Immunodeficiency Virus ◽  
Hiv 1

The virus population transmitted by a human immunodeficiency virus type 1 (HIV-1) infected individual undergoes restriction and subsequent diversification in the new host. However, in contrast to men, who have limited virus diversity at seroconversion, there is measurable diversity in viral envelope gene sequences in women infected with clade A HIV-1. In this study, virus sequence diversity in three unrelated, clade A infected women preceding and shortly after seroconversion was evaluated. It was demonstrated that there is measurable evolution of envelope gene sequences over this time interval. Furthermore, in each of the three individuals, amino acid substitutions arose at five or six positions in sequences derived at or shortly after seroconversion relative to sequences obtained from the seronegative sample. Presented here is a model of clade A gp120 to determine the location of substitutions that appeared as the virus population became established in three clade A HIV-1 infected women.

scholarly journals Evaluation of a prototype sub-unit vaccine against equine arteritis virus comprising the entire ectodomain of the virus large envelope glycoprotein (GL): induction of virus-neutralizing antibody and assessment of protection in ponies

2001 ◽  
Vol 82 (10) ◽  
pp. 2425-2435 ◽  
Author(s):  
J. Castillo-Olivares ◽  
A. A. F. de Vries ◽  
M. J. B. Raamsman ◽  
P. J. M. Rottier ◽  
K. Lakhani ◽  
...  
Keyword(s):  
Envelope Glycoprotein ◽  
Neutralizing Antibody ◽  
Equine Arteritis Virus ◽  
Post Vaccination ◽  
Degree Of Protection ◽  
Glycoprotein G ◽  
Virus Excretion ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Immunization Study

An Escherichia coli-expressed recombinant protein (6hisGLecto) comprising the entire ectodomain (aa 18–122) of equine arteritis virus (EAV) glycoprotein GL, the immunodominant viral antigen, induced higher neutralizing antibody titres than other GL-derived polypeptides when compared in an immunization study in ponies. The potential of the recombinant GL ectodomain to act as a sub-unit vaccine against EAV was evaluated further in three groups of four ponies vaccinated with doses of 35, 70 or 140 μg of protein. All vaccinated animals developed a virus-neutralizing antibody (VNAb) response with peak titres 1–2 weeks after the administration of a booster on week 5 (VNAb titres of 1·8–3·1), 13 (VNAb titres of 1·4–2·9) or 53 (VNAb titres of 1·2–2·3). Vaccinated and unvaccinated control ponies were infected with EAV at different times post-vaccination to obtain information about the degree of protection relative to the levels of pre-challenge VNAb. Vaccination conferred varying levels of protection, as indicated by reduced or absent pyrexia, viraemia and virus excretion from the nasopharynx. The degree of protection correlated well with the levels of pre-challenge VNAb and, in particular, with levels of virus excretion. These results provide the first evidence that a sub-unit vaccine protects horses against EAV. The use of the sub-unit vaccine in combination with a differential diagnostic test based on other EAV antigens would enable serological discrimination between naturally infected and vaccinated equines.

scholarly journals Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection

2007 ◽  
Vol 81 (12) ◽  
pp. 6187-6196 ◽  
Author(s):  
E. S. Gray ◽  
P. L. Moore ◽  
I. A. Choge ◽  
J. M. Decker ◽  
F. Bibollet-Ruche ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Subtype C ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT The study of the evolution and specificities of neutralizing antibodies during the course of human immunodeficiency virus type 1 (HIV-1) infection may be important in the discovery of possible targets for vaccine design. In this study, we assessed the autologous and heterologous neutralization responses of 14 HIV-1 subtype C-infected individuals, using envelope clones obtained within the first 2 months postinfection. Our data show that potent but relatively strain-specific neutralizing antibodies develop within 3 to 12 months of HIV-1 infection. The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region. Anti-MPER antibodies were detected in 4 of 14 individuals within a year of infection, while antibodies to CD4-induced (CD4i) epitopes developed to high titers in 12 participants, in most cases before the development of autologous neutralizing antibodies. However, neither anti-MPER nor anti-CD4i antibody specificity conferred neutralization breadth. These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection.

Sign in / Sign up

Export Citation Format

Share Document